Research programme: therapeutics - Re-Pharm

Drug Profile

Research programme: therapeutics - Re-Pharm

Alternative Names: RP 0217

Latest Information Update: 02 Aug 2016

Price : $50

At a glance

  • Originator Re-Pharm
  • Class Anti-inflammatories; Fluoroquinolones; Naphthyridines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Eye disorders; Inflammatory bowel diseases; Respiration disorders
  • Research Neuropathic pain; Sexual function disorders

Most Recent Events

  • 02 Aug 2016 Early research in Sexual function disorders in United Kingdom (unspecified route)
  • 02 Aug 2016 Early research in Neuropathic pain in United Kingdom (unspecified route)
  • 02 Aug 2016 Preclinical trials in Inflammatory bowel disease in United Kingdom (Topical) before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top